General Information
|
|
Product
|
CDKN2A / p14ARF Antibody FITC
|
Description
|
FITC-Conjugated partial tumor supressor p14ARF Antibody N-epitope
|
Verified Applications
|
ELISA, IHC, IP, WB
|
Host
|
Rabbit
|
Species Cross Reactivity
|
Human, Monkey, Mouse, Rat
|
Immunogen
|
N-epitope synthetic peptide corresponding to unique amino acid sequence on p14ARF protein
|
Accession #
|
GenBank: AAC6069.1
|
Physical Properties
|
|
Quantity
|
100 µg
|
Volume
|
200 µl
|
Concentration
|
1.00-1.25 mg/ml µg/µl in antibody stabilization buffer
|
Form
|
FITC-Conjugated
|
Clonality
|
Polyclonal
|
Determinant
|
N-epitope
|
Storage
|
-20⁰C for long term storage
|
Application Protocol
|
DB
|
1:10,000
|
ELISA
|
1:10,000
|
Immunohistochemistry |
1:100 |
Immunoprecipitation |
1:200 |
Western Blot
|
1:500
|
Protein
|
Uniprot #
|
Q8N726
|
Overview
|
Functions as a tumor supressor and has the ability to induce cell cycle arrest in the G1 and G2 phases. Serves to induce G2 arrest and apoptosis in a p53-independent manner via preventing the activation of cyclin B1/CDC2 complexes.
|
Molecular Function
|
DNA binding, RNA binding, p53 binding, MDM2/MDM4 family protein binding
|
Subcellular Location
|
Nucleus
|
Structure
|
No interaction with cyclins, CDK1, CDK2, CDK4, CDK5 or CDK6. Interacts with TBRG1, COMMD1, CDKN2AIP and E4F1. Binds to BCL6, E2F1, HUWE1, MDM2, MYC, NPM1/B23, TOP1/TOPOI and UBE2I/UBC9.
|
Alternative Nomenclature
|
ARF antibody
CDK4 inhibitor p16 INK4 antibody
CDK4I antibody
CDKN 2A antibody
Cell cycle negative regulator beta antibody
CMM2 antibody
Cyclin dependent kinase 4 inhibitor A antibody
1/2/3 antibody
Cyclin dependent kinase inhibitor p16 antibody
INK4 antibody
Melanoma p16 inhibits CDK4 antibody
MLM antibody
MTS 1 antibody
p14 antibody
p16 antibody
p19 antibody
P19ARF antibody
TP16 antibody
|
|
|